Products for Research Use Only
RegisterLogin

HNHA

CAT: 0804-HY-118672-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-118672-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
HNHA is a potent HDAC inhibitor with an IC50 of 100 nM. HNHA arrests the cell cycle at the G1/S phase via p21 induction. HNHA inhibits tumor growth and tumor neovascularization. HNHA may be a potent anti-cancer agent against breast cancer[1].
CAS Number
926908-04-5
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
HDAC; HIF/HIF Prolyl-Hydroxylase; MMP
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/hnha.html
Purity
99.76
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NO)CCCCCCSC1=CC=C2C=CC=CC2=C1
Molecular Formula
C17H21NO2S
Molecular Weight
303.42
Precautions
H302, H315, H319, H335
References & Citations
[1]Park KC, et al. Potential anti-cancer activity of N-hydroxy-7- (2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo. Cancer Sci. 2011 Feb;102 (2) :343-50.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MMP-2; MMP-9

Alternative Products

CatalogName
B2821-5HNHA

Popular Products